Literature DB >> 2033260

Human extracellular recombinant phospholipase A2 induces an inflammatory response in rabbit joints.

J S Bomalaski1, P Lawton, J L Browning.   

Abstract

Phospholipase A2 (PLA2) enzymes hydrolyze membrane phospholipids liberating fatty acid and lysophospholipid. This event is thought to be the rate-limiting step in the generation of the lipid proinflammatory mediators, the eicosanoids and possibly platelet-activating factor. For this reason, extracellular forms of PLA2 have been postulated to be a component of the inflammatory cascade in certain biologic settings. In the synovial fluid of patients with inflammatory arthritides, substantial amounts of PLA2 activity have been found, and subsequently, one enzyme was purified, cloned, and expressed. Here we show that the pure recombinant enzyme free of any proinflammatory contaminants elicits a dramatic inflammatory, arthritogenic response when injected into the joint space of healthy rabbits. Within 24 h, extensive leukocyte infiltration and hyperplasia of the synovial lining cells were observed, and prostaglandin production in the joint space increased. In comparison, pancreatic PLA2(2) had little activity in this system, whereas a very inflammatory cobra venom enzyme was intermediate in its effects. In view of the presence of the enzyme in inflamed joints, the fact that its synthesis and secretion can be induced by proinflammatory cytokines and its proinflammatory biologic activity, we suggest that synovial PLA2 plays an exacerbating role in acute episodes in chronic inflammatory conditions such as rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2033260

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

Review 1.  Benefits and risks of minocycline in rheumatoid arthritis.

Authors:  P Langevitz; A Livneh; I Bank; M Pras
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

2.  Enzymatic activity and immunoreactivity of extracellular phospholipase A2 in inflammatory synovial fluids.

Authors:  W Pruzanski; K Scott; G Smith; I Rajkovic; E Stefanski; P Vadas
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

Review 3.  Antigenic specificities of "antiphospholipid" autoantibodies.

Authors:  R A Roubey
Journal:  Springer Semin Immunopathol       Date:  1994

4.  Increased activity of group II phospholipase A2 in plasma in rat sodium deoxycholate induced acute pancreatitis.

Authors:  S Furue; Y Hori; K Kuwabara; J Ikeuchi; H Onoyama; M Yamamoto; K Tanaka
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

5.  Induction of secretory phospholipase A2 confirms the systemic inflammatory nature of adjuvant arthritis.

Authors:  M K Lin; A Katz; H van den Bosch; B Kennedy; E Stefanski; P Vadas; W Pruzanski
Journal:  Inflammation       Date:  1998-04       Impact factor: 4.092

6.  Regulation of arachidonic acid, eicosanoid, and phospholipase A2 levels in murine mast cells by recombinant stem cell factor.

Authors:  A N Fonteh; J M Samet; F H Chilton
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

7.  Antiinflammatory action of thielocin A1 beta, a group II phospholipase A2 specific inhibitor, in rat carrageenan-induced pleurisy.

Authors:  K Tanaka; T Kato; K Matsumoto; T Yoshida
Journal:  Inflammation       Date:  1993-04       Impact factor: 4.092

8.  Human recombinant platelet phospholipase A2 exacerbates poly-L-arginine induced rat paw edema.

Authors:  G Cirino; C Cicala; L Sorrentino
Journal:  Inflammation       Date:  1994-02       Impact factor: 4.092

9.  Design of group IIA secreted/synovial phospholipase A(2) inhibitors: an oxadiazolone derivative suppresses chondrocyte prostaglandin E(2) secretion.

Authors:  Jean-Edouard Ombetta; Natacha Thelier; Chang Zhi Dong; Stéphanie Plocki; Lydia Tsagris; François Rannou; France Massicot; Atimé Djimdé; Elissar El-Hayek; Yiming Shi; Françoise Heymans; Nohad Gresh; Caroline Chauvet
Journal:  PLoS One       Date:  2010-06-01       Impact factor: 3.240

10.  Differential inhibition of human secretory and cytosolic phospholipase A2.

Authors:  F Märki; W Breitenstein; E Beriger; R Bernasconi; G Caravatti; J E Francis; R Paioni; H U Wehrli; R Wiederkehr
Journal:  Agents Actions       Date:  1993-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.